Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review

References

• Falcone I, Conciatori F, Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, Milella M. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. Cancers (Basel). 2020;12(10):1–8. doi:https://doi.org/10.3390/cancers12102870.
   Web of Science ®Google Scholar
• Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, et al. Melanoma immunotherapy. Cancer Biol Ther. 2014;15(6):665–74. doi:https://doi.org/10.4161/cbt.28555.
   PubMed Web of Science ®Google Scholar
• Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Wspolczesna Onkol. 2018;22:61–67. doi:https://doi.org/10.5114/wo.2018.73889.
   Google Scholar
• Simsek M, Tekin SB, Bilici M. Immunological agents used in cancer treatment. Eurasian J Med. 2019;51(1):90–94. doi:https://doi.org/10.5152/eurasianjmed.2018.18194.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Agarwala SS, Ciliberto G, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V. Future perspectives in melanoma research “Melanoma bridge”, Napoli, November 30th-3rd December 2016. J Transl Med. 2017;15(1):1–31. doi:https://doi.org/10.1186/s12967-017-1341-2.
   PubMed Web of Science ®Google Scholar
• Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol. 2020;93(1109):20200042. doi:https://doi.org/10.1259/bjr.20200042.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Formenti SC, Demaria S. TREX1 dictates the immune fate of irradiated cancer cells. Oncoimmunology. 2017;6(9):e1339857. doi:https://doi.org/10.1080/2162402X.2017.1339857.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Uveal melanoma. (version 2.2020) [accessed 2020 Dec 15]. https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf .
   Google Scholar
• Tazi K, Hathaway A, Chiuzan C, Shirai K. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med. 2015;4(1):1–6. doi:https://doi.org/10.1002/cam4.315.
   PubMed Web of Science ®Google Scholar
• Trommer-Nestler M, Marnitz S, Kocher M, Rueß D, Schlaak M, Theurich S, Von Bergwelt-baildon M, Morgenthaler J, Jablonska K, Celik E. Robotic stereotactic radiosurgery in melanoma patients with brain metastases under simultaneous anti-PD-1 treatment. Int J Mol Sci. 2018;19(9):2653. doi:https://doi.org/10.3390/ijms19092653.
   Web of Science ®Google Scholar
• Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899–906. doi:https://doi.org/10.1002/cam4.140.
   PubMed Web of Science ®Google Scholar
• Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, Golfinos JG, Parker EC, Huang PP, Narayana A. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23(3):191–95. doi:https://doi.org/10.1097/CMR.0b013e32835f3d90.
   PubMed Web of Science ®Google Scholar
• Pauline T, Clara A, Bastien O, Dalle S, Mortier L, Leccia M-T, Guillot B, Dalac S, Dutriaux C, Lacour J-P. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. Eur J Cancer. 2019;112(February):38–46. doi:https://doi.org/10.1016/j.ejca.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015;3(1). doi:https://doi.org/10.1186/s40425-015-0095-8.
   Google Scholar
• Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, et al. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. Eur J Cancer. 2019;110:11–20. doi:https://doi.org/10.1016/j.ejca.2018.12.023.
   PubMed Web of Science ®Google Scholar
• Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368–75. doi:https://doi.org/10.1016/j.ijrobp.2015.01.004.
   PubMed Web of Science ®Google Scholar
• An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D’Souza NM, Haydu LE, Wang XA, et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017;125(1):80–88. doi:https://doi.org/10.1016/j.radonc.2017.08.009.
   PubMed Web of Science ®Google Scholar
• Jasińska-Konior K, Pochylczuk K, Czajka E, Michalik M, Romanowska-Dixon B, Swakoń J, Urbańska K, Elas M. Proton beam irradiation inhibits the migration of melanoma cells. PLoS One. 2017;12(10):1–16. doi:https://doi.org/10.1371/journal.pone.0186002.
   Web of Science ®Google Scholar
• Ando K, Fujita H, Hosoi A, Ma L, Wakatsuki M, Seino K-I, Kakimi K, Imai T, Shimokawa T, Nakano T. Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. J Radiat Res. 2017;58(4):446–55. doi:https://doi.org/10.1093/jrr/rrx005.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Garasa S, Rodriguez I, Solorzano JL, Barbes B, Yanguas A, Teijeira A, Etxeberria I, Aristu JJ, Halin C. Intercellular adhesion molecule-1 and vascular cell adhesion molecule are induced by ionizing radiation on lymphatic endothelium. Int J Radiat Oncol Biol Phys. 2017;97(2):389–400. doi:https://doi.org/10.1016/j.ijrobp.2016.10.043.
   PubMed Web of Science ®Google Scholar
• Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US. Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol. 2016;6(JUN):1–16. doi:https://doi.org/10.3389/fonc.2016.00141.
   PubMed Web of Science ®Google Scholar
• Fionda B, Massaccesi M, Tagliaferri L, Dinapoli N, Iezzi R, Boldrini L. Abscopal effect and interventional oncology: state of art and future perspectives. Eur Rev Med Pharmacol Sci. 2020;24(2):773–76. doi:https://doi.org/10.26355/eurrev_202001_20058.
   PubMed Web of Science ®Google Scholar
• Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219–35. doi:https://doi.org/10.1093/annonc/mdy551.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–77. doi:https://doi.org/10.1038/nature14292.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Reddy SA, Maecker HT, Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, Saha S, Shura L, Knox SJ. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys. 2016;96(3):578–88. doi:https://doi.org/10.1016/j.ijrobp.2016.07.005.
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1(2):92–98. doi:https://doi.org/10.1158/2326-6066.CIR-13-0082.
   PubMed Web of Science ®Google Scholar
• Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5(9):e1214788. doi:https://doi.org/10.1080/2162402X.2016.1214788.
   PubMed Web of Science ®Google Scholar
• Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4(11):e1046028. doi:https://doi.org/10.1080/2162402X.2015.1046028.
   PubMed Web of Science ®Google Scholar
• Kato J, Hida T, Someya M, Sato S, Sawada M, Horimoto K, Fujioka M, Minowa T, Matsui Y, Tsuchiya T. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma. J Dermatol. 2019;46(4):328–33. doi:https://doi.org/10.1111/1346-8138.14805.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Chang JS, Roh MR, Oh BH, Chung K-Y, Shin SJ, Koom WS. Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients. Front Oncol. 2019;9(September):1–9. doi:https://doi.org/10.3389/fonc.2019.00835.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:https://doi.org/10.3322/caac.21388.
   PubMed Web of Science ®Google Scholar
• Weitman ES, Perez M, Thompson JF, Andtbacka RHI, Dalton J, Martin ML, Miller T, Gwaltney C, Sarson D, Wachter E. Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Res. 2018;28(2):134–42. doi:https://doi.org/10.1097/CMR.0000000000000425.
   PubMed Web of Science ®Google Scholar
• Teterycz P, Ługowska I, Koseła-Paterczyk H, Rutkowski P. Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. World J Surg Oncol. 2019;17(1):1–7. doi:https://doi.org/10.1186/s12957-019-1669-6.
   PubMed Web of Science ®Google Scholar
• Weitman ES, Zager JS. Regional therapies for locoregionally advanced and unresectable melanoma. Clin Exp Metastasis. 2018;35(5–6):495–502. doi:https://doi.org/10.1007/s10585-018-9890-1.
   PubMed Web of Science ®Google Scholar
• Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res. 2016;4(9):744–54. doi:https://doi.org/10.1158/2326-6066.CIR-15-0156.
   PubMed Web of Science ®Google Scholar
• Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A, Brochez L, Kruse V, Ost P. Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. Int J Radiat Oncol Biol Phys. 2019;104(4):828–35. doi:https://doi.org/10.1016/j.ijrobp.2019.03.041.
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004;30(6):515–20. doi:https://doi.org/10.1016/j.ctrv.2004.05.001.
   PubMed Web of Science ®Google Scholar
• Skibber JM, Soong S-J, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol. 1996;3(2):118–23. doi:https://doi.org/10.1007/BF02305789.
   PubMed Web of Science ®Google Scholar
• Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, Kirkwood JM, Tarhini A, Moschos S, Lunsford LD, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases: clinical article. J Neurosurg. 2011;114(3):769–79. doi:https://doi.org/10.3171/2010.5.JNS1014.
   PubMed Web of Science ®Google Scholar
• Neal MT, Chan MD, Lucas JT, Loganathan A, Dillingham C, Pan E, Stewart JH, Bourland JD, Shaw EG, Tatter SB. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. 2014;82(6):1250–55. doi:https://doi.org/10.1016/j.wneu.2013.02.025.
   PubMed Web of Science ®Google Scholar
• Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, Chenevert TL, Lawrence TS. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23(18):4127–36. doi:https://doi.org/10.1200/JCO.2005.07.144.
   PubMed Web of Science ®Google Scholar
• Corso CD, Ali AN, Diaz R. Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res. 2011;1(3):390–412. http://www.ncbi.nlm.nih.gov/pubmed/21969260%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3180059 .
   PubMed Web of Science ®Google Scholar
• Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with TH1 cell therapy. Cancer Res. 2010;70(7):2697–706. doi:https://doi.org/10.1158/0008-5472.CAN-09-2982.
   PubMed Web of Science ®Google Scholar
• Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival: clinical article. J Neurosurg. 2012;117(2):227–33. doi:https://doi.org/10.3171/2012.5.JNS111929.
   PubMed Web of Science ®Google Scholar
• Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer. 2017;75:169–78. doi:https://doi.org/10.1016/j.ejca.2017.01.007.
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard MA, Régis JM. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017;84:44–54. doi:https://doi.org/10.1016/j.ejca.2017.07.017.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016;27(12). doi:https://doi.org/10.1093/annonc/mdw417.
   Google Scholar
• Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, Khosa F, Liu Y, Khan MK. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol Cancer Clin Trials. 2017;40(5):444–50. doi:https://doi.org/10.1097/COC.0000000000000199.
   PubMed Web of Science ®Google Scholar
• Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572–76.
   PubMedGoogle Scholar
• Watanabe T, Firat E, Scholber J, Gaedicke S, Heinrich C, Luo R, Ehrat N, Multhoff G, Schmitt-Graeff A, Grosu A-L. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunol Immunother. 2020;69(9):1823–32. doi:https://doi.org/10.1007/s00262-020-02587-8.
   PubMed Web of Science ®Google Scholar
• Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72. doi:https://doi.org/10.1158/2326-6066.CIR-13-0115.
   PubMed Web of Science ®Google Scholar
• Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review. Clin Transl Radiat Oncol. 2018;9:5–11. doi:https://doi.org/10.1016/j.ctro.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344–51. doi:https://doi.org/10.1016/j.ijrobp.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, Delord J-P, Chira C, Delannes M, Moyal E. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. Melanoma Res. 2017;27(5):485–91. doi:https://doi.org/10.1097/CMR.0000000000000386.
   PubMed Web of Science ®Google Scholar
• Gabani P, Robinson CG, Ansstas G, Johanns TM, Huang J. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. Radiother Oncol. 2018;127(2):310–17. doi:https://doi.org/10.1016/j.radonc.2018.02.022.
   PubMed Web of Science ®Google Scholar
• Selby HM, Sherman RS, Pack GT, Roentgen A. Study of bone metastases from melanoma. Radiology. 1956;67(2):224–28. doi:https://doi.org/10.1148/67.2.224.
   PubMed Web of Science ®Google Scholar
• Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:1–9. doi:https://doi.org/10.1155/2012/647684.
   Google Scholar
• National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer stat facts: melanoma of the skin. [accessed 2020 Dec 15]. https://seer.cancer.gov/statfacts/html/melan.html .
   Google Scholar
• Mannavola F, Mandala M, Todisco A, Sileni VC, Palla M, Minisini AM, Pala L, Morgese F, Di Guardo L, Stucci LS, et al. An Italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival. Front Oncol. 2020;10(September):1–11. doi:https://doi.org/10.3389/fonc.2020.01652.
   PubMed Web of Science ®Google Scholar
• Wang S-J, Jhawar SR, Rivera-Nunez Z, Silk AW, Byun J, Miller E, Blakaj D, Parikh RR, Weiner J, Goyal S, et al. The association of radiation dose-fractionation and immunotherapy use with overall survival in metastatic melanoma patients. Cureus. 2020;12(6). doi:https://doi.org/10.7759/cureus.8767.
   Google Scholar
• Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys. 1999;44(3):607–18. doi:https://doi.org/10.1016/S0360-3016(99)00066-8.
   PubMed Web of Science ®Google Scholar
• Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A, Kachnic L, Lo S, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965–76. doi:https://doi.org/10.1016/j.ijrobp.2010.11.026.
   PubMed Web of Science ®Google Scholar
• Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology. 1987;164(3):607–10. doi:https://doi.org/10.1148/radiology.164.3.3112864.
   PubMed Web of Science ®Google Scholar
• Rounsaville MC, Cantril ST, Fontanesi J, Vaeth JM, Green JP. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. Front Radiat Ther Oncol. 1988;22:62–78. doi:https://doi.org/10.1159/000415097.
   PubMedGoogle Scholar
• Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int J Radiat Oncol Biol Phys. 1981;7(7):897–906. doi:https://doi.org/10.1016/0360-3016(81)90006-7.
   PubMed Web of Science ®Google Scholar
• Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys. 1988;15(4):859–64. doi:https://doi.org/10.1016/0360-3016(88)90118-6.
   PubMed Web of Science ®Google Scholar
• Haymaker CL, Kim DW, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C. Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res. 2017;5(2):100–05. doi:https://doi.org/10.1158/2326-6066.CIR-16-0223.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Kim S, Harrison LB. Novel opportunities to use radiation therapy with immune checkpoint inhibitors for melanoma management. Surg Oncol Clin N Am. 2017;26(3):515–29. doi:https://doi.org/10.1016/j.soc.2017.01.007.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P. Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol. 2016;120(1):1–12. doi:https://doi.org/10.1016/j.radonc.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65. doi:https://doi.org/10.1093/jnci/djs629.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Haffty B. Radiotherapy as a new player in immuno-oncology. Cancers (Basel). 2018;10(12):515. doi:https://doi.org/10.3390/cancers10120515.
   Web of Science ®Google Scholar
• Mazzola R, Jereczek-Fossa BA, Franceschini D, Tubin S, Filippi AR, Tolia M, Lancia A, Minniti G, Corradini S, Arcangeli S, et al. Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiat Oncol. 2020;15(1):1–13. doi:https://doi.org/10.1186/s13014-020-01544-0.
   Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31. doi:https://doi.org/10.1056/nejmoa1112824.
   PubMed Web of Science ®Google Scholar
• Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2: tumor and immunological responses. Sci Transl Med. 2012;4(137):1–8. doi:https://doi.org/10.1126/scitranslmed.3003649.
   Web of Science ®Google Scholar
• Bang A, Schoenfeld JD. Immunotherapy and radiotherapy for metastatic cancers. Ann Palliat Med. 2019;8(3):312–25. doi:https://doi.org/10.21037/apm.2018.07.10.
   PubMed Web of Science ®Google Scholar
• Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):571–79. doi:https://doi.org/10.1016/j.ijrobp.2015.11.026.
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95. doi:https://doi.org/10.1182/blood-2009-02-206870.
   PubMed Web of Science ®Google Scholar
• Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013;31(2):140–44. doi:https://doi.org/10.3109/07357907.2012.762780.
   PubMed Web of Science ®Google Scholar
• Bol KF, Donia M, Heegaard S, Kiilgaard JF, Svane IM. Genetic biomarkers in melanoma of the ocular region: what the medical oncologist should know. Int J Mol Sci. 2020;21(15):1–14. doi:https://doi.org/10.3390/ijms21155231.
   Web of Science ®Google Scholar
• Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7(4):4624–31. doi:https://doi.org/10.18632/oncotarget.6614.
   PubMedGoogle Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. doi:https://doi.org/10.1038/nature12477.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–01. doi:https://doi.org/10.1056/nejmc1713444.
   PubMed Web of Science ®Google Scholar
• Taylor AW. Ocular immune privilege and transplantation. Front Immunol. 2016;7(February):14–16. doi:https://doi.org/10.3389/fimmu.2016.00037.
   PubMed Web of Science ®Google Scholar
• Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M, Berking C, Heppt MV. The role of immune checkpoint blockade in uveal melanoma. Int J Mol Sci. 2020;21(3):1–32. doi:https://doi.org/10.3390/ijms21030879.
   Web of Science ®Google Scholar
• Rodrigues M, De Koning L, Coupland SE, Jochemsen A, Marais R, Stern M-H, Valente A, Barnhill R, Cassoux N, Evans A, et al. So close, yet so far: discrepancies between uveal and other melanomas. a position paper from UM cure 2020. Cancers (Basel). 2019;11(7):1032. doi:https://doi.org/10.3390/cancers11071032.
   PubMed Web of Science ®Google Scholar
• Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, et al. Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? Cancers (Basel). 2019;11(8):1–12. doi:https://doi.org/10.3390/cancers11081055.
   Web of Science ®Google Scholar
• Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185–204. doi:https://doi.org/10.1586/17469899.2014.921119.
   PubMedGoogle Scholar
• Sagiv O, Thakar SD, Kandl TJ, Ford J, Sniegowski MC, Hwu W-J, Esmaeli B. Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol. 2018;136(11):1236–41. doi:https://doi.org/10.1001/jamaophthalmol.2018.3488.
   PubMed Web of Science ®Google Scholar
• Finger PT, Pavlick AC. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. J Immunother Cancer. 2019;7(1):1–7. doi:https://doi.org/10.1186/s40425-019-0555-7.
   PubMed Web of Science ®Google Scholar
• Garcovich S, Colloca G, Sollena P, Andrea B, Balducci L, Cho WC, Bernabei R, Peris K. Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 2017;8(5):643–61. doi:https://doi.org/10.14336/AD.2017.0503.
   PubMed Web of Science ®Google Scholar
• Perier-Muzet M, Gatt E, Péron J, Falandry C, Amini-Adlé M, Thomas L, Dalle S, Boespflug A. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol. 2018;154(1):82–87. doi:https://doi.org/10.1001/jamadermatol.2017.4584.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54. doi:https://doi.org/10.1111/j.1749-6632.2000.tb06651.x.
   PubMed Web of Science ®Google Scholar
• Fulop T, Le Page A, Fortin C, Witkowski JM, Dupuis G, Larbi A. Cellular signaling in the aging immune system. Curr Opin Immunol. 2014;29(1):105–11. doi:https://doi.org/10.1016/j.coi.2014.05.007.
   PubMed Web of Science ®Google Scholar
• Colloca G, Di Capua B, Bellieni A, Fusco D, Ciciarello F, Tagliaferri L, Valentini V, Balducci L. Biological and functional biomarkers of aging: definition, characteristics, and how they can impact everyday cancer treatment. Curr Oncol Rep. 2020;22(11). doi:https://doi.org/10.1007/s11912-020-00977-w.
   Google Scholar
• Colloca G, Lattanzio F, Balducci L, Onder G, Ronconi G, Landi F, Morlans G, Bernabei R. Treating cancer and no-cancer pain in older and oldest old patients. Curr Pharm Des. 2015;21(13). doi:https://doi.org/10.2174/1381612821666150130124926.
   Google Scholar
• Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, Falandry C, Artz A, Brain E, Colloca G. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603. doi:https://doi.org/10.1200/JCO.2013.54.8347.
   PubMed Web of Science ®Google Scholar
• Colloca G, Santoro M, Gambassi G. Age-related physiologic changes and perioperative management of elderly patients. Surg Oncol. 2010;19(3):124–30. doi:https://doi.org/10.1016/j.suronc.2009.11.011.
   PubMed Web of Science ®Google Scholar
• Colloca G, Tagliaferri L, Di Capua B, Gambacorta MA, Lanzotti V, Bellieni A, Monfardini S, Balducci L, Bernabei R, Cho WC. Management of the elderly cancer patients complexity: the radiation oncology potential. Aging Dis. 2020;11(3):649–57. doi:https://doi.org/10.14336/AD.2019.0616.
   PubMed Web of Science ®Google Scholar
• Colloca G, Di Capua B, Bellieni A, Cesari M, Marzetti E, Valentini V, Calvani R. Muscoloskeletal aging, sarcopenia and cancer. J Geriatr Oncol. 2019;10(3):504–09. doi:https://doi.org/10.1016/j.jgo.2018.11.007.
   PubMed Web of Science ®Google Scholar